LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Open

12.03 -2.67

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.18

Max

12.67

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+156.7% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-18M 1.3B
Vorige openingsprijs	14.7
Vorige sluitingsprijs	12.03

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mei 2026, 23:53 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mei 2026, 23:50 UTC

Marktinformatie

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mei 2026, 23:36 UTC

Marktinformatie

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mei 2026, 23:07 UTC

Acquisities, Fusies, Overnames

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

UOB: Share Sale Agreements Entered With Singland Properties

17 mei 2026, 23:05 UTC

Acquisities, Fusies, Overnames

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire Stake for $389 Million

17 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mei 2026, 16:27 UTC

Acquisities, Fusies, Overnames

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mei 2026, 15:26 UTC

Acquisities, Fusies, Overnames

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mei 2026, 08:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

156.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 156.7%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.